Labcorp announces 2024 fourth quarter and full year results

Company provides 2025 guidance results from continuing operations versus last year: revenue: q4 of $3.33 billion vs $3.03 billion; full year of $13.01 billion vs $12.16 billion diluted eps: q4 of $1.70 vs $(1.95); full year of $8.84 vs $4.33 adjusted eps: q4 of $3.45 vs $3.30; full year of $14.57 vs $13.56 free cash flow: q4 of $665.1 million vs $412.4 million; full year of $1.10 billion vs $748.7 million announced 10 transactions and launched new innovative tests meeting significant unmet medical needs in key specialty areas in full year 2024 full-year 2025 guidance: revenue of $13.88 billion to $14.05 billion; midpoint growth of 7.4% adjusted eps of $15.60 to $16.40; midpoint growth of 9.8% free cash flow of $1.10 billion to $1.25 billion; midpoint growth of 7.2% burlington, n.c. , feb. 6, 2025 /prnewswire/ -- labcorp holdings inc. (nyse: lh), a global leader of innovative and comprehensive laboratory services, today announced results for the fourth quarter ended december 31, 2024, and provided 2025 guidance.
LH Ratings Summary
LH Quant Ranking